数据显示，东方阿尔法基金旗下1只基金重仓舒泰神。东方阿尔法健康产业混合发起A（024357）三季 度增持22.3万股，持有股数23.95万股，占基金净值比例为6.08%，位居第八大重仓股。根据测算，今日 浮亏损失约39.51万元。连续5天下跌期间浮亏损失176.72万元。 东方阿尔法健康产业混合发起A（024357）成立日期2025年6月12日，最新规模3539.51万。成立以来亏 损4.69%。 东方阿尔法健康产业混合发起A（024357）基金经理为孟昱。 11月24日，舒泰神跌5.17%，截至发稿，报30.27元/股，成交3.80亿元，换手率2.67%，总市值144.62亿 元。舒泰神股价已经连续5天下跌，区间累计跌幅18.78%。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 从基金十大重仓股角度 截至发稿，孟昱累计任 ...

Core Viewpoint - The company has recently obtained a new drug production license from the Beijing Municipal Drug Administration, which is a significant regulatory milestone for its operations [2]. Group 1 - The company, Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd., has received a drug production license, allowing it to enhance its manufacturing capabilities [2]. - Following the acquisition of the drug production license, the company applied for a new business license from the Beijing Economic and Technological Development Zone Market Supervision Administration [2]. - The company has completed the business registration change procedures and obtained a new "Enterprise Legal Person Business License" from the relevant authority [2].

证券代码：300204 证券简称：舒泰神 公告编号：2025-081 舒泰神（北京）生物制药股份有限公司 关于换发药品生产许可证及营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、舒泰神（北京）生物制药股份有限公司（以下简称"公司"）于近期取 得了北京市药品监督管理局换发的药品生产许可证，主要信息如下： 企业名称：舒泰神（北京）生物制药股份有限公司 北京市北京经济技术开发区经海二路 36 号：口服溶液剂、散剂、片剂、治 疗用生物制品*** 社会信用代码：911100007423131451 注册地址：北京市北京经济技术开发区经海二路 36 号 法定代表人：周志文 企业负责人：王超 质量负责人：刘晓宁 有效期至：2030 年 11 月 02 日 许可证编号：京 20150112 分类码：AhsBsCs 生产地址和生产范围： 北京市北京经济技术开发区瑞合西一路 7 号院（北京昭衍生物技术有限公 司）：治疗用生物制品*** 二、基于上述药品生产许可证信息，根据《药品生产监督管理办法》的要求， 公司向北京经济技术开发区市场监督管理局申请换发了营业执照 ...

Core Points - The Shanghai Composite Index is at 3948.89 points with a slight increase of 0.05% as of 10:33 AM, and the total trading volume of A-shares is 851.994 billion yuan [1] - A total of 98 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stocks with Significant Moving Average Crosses - Bawei Storage (688525) has a 5-day moving average of 122.55 yuan, which is 2.96% lower than its 10-day moving average of 126.29 yuan, with a current price of 113.88 yuan, down 3.24% today [1] - Jinkai Biological (301509) shows a 5-day moving average of 37.52 yuan, down 1.69% from its 10-day moving average of 38.17 yuan, currently priced at 34.13 yuan, down 6.49% [1] - Shutaishen (300204) has a 5-day moving average of 35.59 yuan, which is 1.41% lower than its 10-day moving average of 36.09 yuan, with a current price of 33.40 yuan, down 2.34% [1] Group 2: Additional Stocks with Moving Average Crosses - Tongli Rising (605286) has a 5-day moving average of 42.55 yuan, down 1.39% from its 10-day moving average of 43.14 yuan, currently priced at 40.40 yuan, down 0.20% [1] - Ziran (605080) shows a 5-day moving average of 24.27 yuan, which is 1.25% lower than its 10-day moving average of 24.58 yuan, currently priced at 23.43 yuan, down 1.88% [1] - Yema Battery (605378) has a 5-day moving average of 25.22 yuan, down 1.23% from its 10-day moving average of 25.53 yuan, currently priced at 24.03 yuan, down 0.62% [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"）第六届董事会第 十一次会议审议通过了《关于提请召开公司 2025 年第三次临时股东会的议案》， 本次股东会将于 2025 年 11 月 24 日采用现场表决与网络投票相结合的方式召开。 《关于召开 2025 年第三次临时股东会的通知》已于 2025 年 11 月 07 日刊登于中国 证监会指定的创业板信息披露网站。现将会议有关事项提示如下： 一、召开会议的基本情况 证券代码：300204 证券简称：舒泰神 公告编号：2025-080 舒泰神（北京）生物制药股份有限公司 关于召开 2025 年第三次临时股东会的提示性公告 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市 公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关 规定。 4、会议时间： （1）现场会议时间：20 ...

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.02% on November 19, with a trading price of 34.02 CNY per share, reflecting a significant drop in recent trading days despite a substantial year-to-date increase of 359.11% [1] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (Sutai) at 59.17%, compound polyethylene glycol electrolyte powder at 33.19%, and others at 7.63% [1] - The company was established on August 16, 2002, and went public on April 15, 2011 [1] Financial Performance - For the period from January to September 2025, Shuyou Shen reported an operating income of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decline of 227.71% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 46,500, a rise of 46.97%, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings by the third-largest shareholder, Xingquan Helun Mixed A, by 3.45 million shares, and an increase in holdings by the fifth-largest shareholder, Xingquan Heyi Mixed A, by 338,750 shares [3] Market Activity - The stock has seen significant trading activity, with a net outflow of 29.42 million CNY from major funds on November 19, and it has appeared on the trading leaderboard eight times this year, with the most recent instance on October 31, where it recorded a net buy of 373 million CNY [1]

Core Viewpoint - Cancer immunotherapy is emerging as a key treatment method for cancer, following surgery, radiotherapy, and chemotherapy, and is expected to see significant market growth in the coming years [1][6][7]. Group 1: Industry Definition and Classification - Cancer immunotherapy aims to activate or enhance the immune system to target tumor cells, utilizing methods such as cytokine therapy, cancer vaccines, T-cell therapy, and immune checkpoint inhibitors [2][4]. Group 2: Current Development Status - Cancer remains a leading health threat, with over 10 million deaths annually. The global anti-cancer drug market is projected to grow from $150.3 billion in 2020 to $253.3 billion in 2024, with cancer immunotherapy expected to reach $69.91 billion, accounting for 27.60% of the market [4][6][7]. Group 3: Industry Chain - The cancer immunotherapy industry chain includes upstream activities such as basic research and drug design, midstream development and production, and downstream medical institutions and testing agencies [8]. Group 4: Development Environment and Policies - Cancer is the leading cause of death globally, with a low early diagnosis rate in China. The government has implemented policies to enhance cancer prevention and treatment, such as the "Healthy China Action - Cancer Prevention and Control Action Implementation Plan (2023-2030)" [9]. Group 5: Competitive Landscape - The cancer immunotherapy market is characterized by concentrated leadership and technological differentiation, with key players including Legend Biotech, Akeso, I-Mab, Junshi Biosciences, and others. Notable advancements have been made in CAR-T, bispecific antibodies, and NK therapies [10][11]. Group 6: Future Development Directions - While cancer immunotherapy has transitioned from laboratory concepts to clinical practice, challenges such as resistance, toxicity, and accessibility remain. Future advancements may lead to a shift from "prolonging survival" to "functional cure" through interdisciplinary innovation and policy support [12][13].

【#A股全市场百股涨停#，沪深两市成交额1.91万亿】#华盛锂电涨超7%续创新高# 板块方面，能源金属、军工、AI应用等板块涨幅居前，贵金属、医药等板块跌幅居前。 截至收盘，沪指跌0.46%，深成指跌0.11%，创业板指跌0.2%。 据智通财经消息，今日A股市场弱势震荡，沪指低开低走，深成指、创业板指尾盘跌幅有所收窄。沪深 两市成交额1.91万亿，较上一个交易日缩量473亿。 盘面上，热点快速轮动，全市场100只个股涨停。锂电池产业链集体爆发，大中矿业3连板，丰元股份等 10余股涨停。福建板块延续强势，厦工股份10天5板，平潭发展、龙洲股份3连板。AI应用概念快速走 强，三六零、浪潮软件、宣亚国际等多股涨停。军工板块表现活跃，航天发展2连板。下跌方面，医药 概念集体下挫，舒泰神、济民健康等大跌。 ...

Core Viewpoint - The current market adjustment is characterized by a lack of a clear leading sector, with technology stocks facing short-term valuation concerns while cyclical sectors are hindered by mid-term uncertainties [3][4][5]. Market Performance - The Shanghai Composite Index fluctuated around the 4000-point mark, closing at 3972.03 points on November 17, down 0.46%, with total trading volume at 1.91 trillion yuan, a decrease of 473 billion yuan from the previous trading day [3][5]. - Margin trading balances fell below 2.5 trillion yuan, with a total of 2.49 trillion yuan on November 14, marking a reduction of over 100 billion yuan from the previous day [5][6]. Sector Analysis - Technology stocks, which had previously seen significant gains, experienced a pullback, while sectors such as textiles, retail, and pharmaceuticals performed well [5][6]. - On November 17, there was a net outflow exceeding 4 billion yuan from solar equipment and semiconductor sectors, while energy metals and military sectors saw gains [6][7]. Investment Strategy - Analysts suggest that the market is currently in a high-level consolidation phase, with a shift in driving forces from liquidity to fundamentals, indicating a slower upward pace [10][13]. - Investment strategies should focus on technology innovation, consumption recovery, and high-dividend defensive stocks, with an emphasis on AI-related opportunities and stable cash flow sectors like utilities and banks [10][13]. Long-term Outlook - The overall sentiment remains optimistic about a "slow bull" market, with no signs of a market top detected, and a potential for structural rebalancing within the market [9][10]. - The "14th Five-Year Plan" emphasizes risk management and structural reforms, while the "15th Five-Year Plan" focuses on proactive economic growth, which is expected to support the market's long-term trajectory [10][12].

Core Viewpoint - The A-share market is currently experiencing a slow bull market, despite recent adjustments and fluctuations around the 4000-point mark [1][6][7]. Market Performance - The Shanghai Composite Index closed at 3972.03 points on November 17, down 0.46%, with total trading volume at 1.91 trillion yuan, a decrease of 473 billion yuan from the previous trading day [2][3]. - The margin trading balance fell below 2.5 trillion yuan, with a total of 2.49 trillion yuan on November 14, marking a reduction of over 100 billion yuan from the previous day [2][3]. Sector Analysis - Technology stocks have shown a significant pullback, while sectors like textiles, retail, and pharmaceuticals have performed better recently [3][4]. - On November 17, there was a net outflow of over 40 billion yuan from sectors such as photovoltaic equipment and semiconductors, while energy metals and military sectors saw gains [4]. Investment Strategy - Analysts suggest that the market is in a high-level adjustment phase, with a shift in driving forces from liquidity to fundamentals, indicating a slower upward pace [9]. - Investment focus should be on technology innovation, consumer recovery, and high dividend defensive stocks, with an emphasis on sectors like utilities and banks for stable cash flow [9][10]. Future Outlook - The market is expected to undergo a rebalancing of styles, with potential for technology stocks to continue performing well despite a possible decrease in buying power [10]. - The overall sentiment remains optimistic for a slow bull market, driven by AI technology and liquidity, with no signs of a market top yet [6][7].